Cost-effectiveness of osteoporosis screening followed by treatment: The impact of medication adherence

Value in Health

Volumn 13, Issue 4, 2010, Pages 394-401

  Hiligsmann, Mickaël ^a   Gathon, Henry Jean ^a   Bruyère, Olivier ^a   Ethgen, Olivier ^a   Rabenda, Véronique ^a   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

adherence; compliance; cost effectiveness; osteoporosis; persistence; screening

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; UNCERTAINTY; BELGIUM; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; MEDICATION COMPLIANCE; MIDDLE AGED; PHOTON ABSORPTIOMETRY; PROBABILITY; STATISTICAL MODEL;

ABSORPTIOMETRY, PHOTON; AGED; ALENDRONATE; BELGIUM; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MASS SCREENING; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, ECONOMETRIC; OSTEOPOROSIS; QUALITY-ADJUSTED LIFE YEARS;

EID: 77954284615     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00687.x     Document Type: Article

References (54)

1. Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006 17 : 1645 1652.
2. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008 19 : 811 818.
3. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006 81 : 1013 1022.
4. Cleemput I, Kesteloot K, DeGeest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 2002 59 : 65 94.
5. Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001 10 : 601 615.
6. Kanis J, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008 19 : 399 428.
7. Schousboe J. Cost effectiveness of screen-and-treat strategies for low bone mineral density: how do we screen, who do we screen and who do we treat? Appl Health Econ Health Policy 2008 6 : 1 18.
8. Schwenkglenks M, Lippuner K. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int 2007 18 : 1481 1491.
9. Schousboe JT, Ensrud KE, Nyman JA, et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005 53 : 1697 1704.
10. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007 298 : 629 637.
11. Hiligsmann M, Ethgen O, Bruyere O, et al. An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis. Dis Manage Health Outcomes 2008 16 : 429 438.
12. Mueller D, Gandjour A. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Appl Health Econ Health Policy 2008 6 : 113 135.
13. Stevenson M, Lloyd Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005 9 : 1 160.
14. van Staa TP, Kanis JA, Geusens P, et al. The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. Value Health 2007 10 : 348 357.
15. Mueller D, Weyler E, Gandjour A. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics 2008 26 : 513 536.
16. Schott AM, Ganne C, Hans D, et al. Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int 2007 18 : 143 151.
17. Borgstrom F, Johnell O, Kanis JA, et al. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 2006 17 : 1459 1471.
18. Hiligsmann M, Ethgen O, Bruyère O, et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009 12 : 687 696.
19. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008 19 : 385 397.
20. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington DC. 2008, Available at http://www.nof.org/professionals/NOF-Clinicians-Guide.pdf [Accessed April 1, 2009].
21. Hughes DA, Bagust A, Haycox A, et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001 19 : 1185 1197.
22. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008 11 : 44 7.
23. Strom O, Borgstrom F, Kanis JA, et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 2009 20 : 23 34.
24. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998 8 : 468 489.
25. Hiligsmann M, Bruyere O, Ethgen O, et al. Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 2008 43 : 991 994.
26. Dere W, Avouac B, Boers M, et al. Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcif Tissue Int 1998 63 : 93 7.
27. Cleemput I, van Wilder P, Huybrechts M, et al. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 2009 12 : 441 449.
28. Zethraeus N, Borgstrom F, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int 2007 18 : 9 23.
29. Hiligsmann M, Ethgen O, Richy F, et al. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 2008 82 : 288 292.
30. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000 27 : 585 590.
31. Boonen S, Kaufman JM, Reginster JY, et al. Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatments in Belgium. Osteoporos Int 2003 14 : 110 115.
32. Marshall D, Johnell O, Wedel H Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996 312 : 1254 1259.
33. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005 20 : 1185 1194.
34. National Institute for Health and Clinical Excellence (NICE). Systematic reviews of clinical effectiveness prepared for the guideline "Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk:" National Institute for Health and Clinical Excellence, 2008. Available from: http://nice.org.uk/nicemedia/pdf/ OsteoporosisEvidenceReviews190908.pdf [Accessed April 5, 2009].
35. Stock JL, Bell NH, Chesnut CH, 3rd., et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997 103 : 291 297.
36. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000 85 : 3109 3115.
37. Tosteson AN, Jonsson B, Grima DT, et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 2001 12 : 849 857.
38. Strom O, Borgstrom F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007 18 : 1047 1061.
39. Belgian Center for Pharmacotherapeutic Information. Drug directory: bisphosphonates. Available from: http://www.cbip.be/GGR/MPG/MPG-NI.cfm#MP-04090 [Accessed April 5, 2009].
40. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996 348 : 1535 1541.
41. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998 280 : 2077 2082.
42. Belgian Center for Pharmacotherapeutic Information. Drug directory: calcium and vitamin D. Available from: http://www.cbip.be/GGR/MPG/MPG-KAC. CFM#MP-1904 [Accessed April 5, 2009].
43. Hiligsmann M, Bruyere O, Pire G, et al. Economic evaluation of osteoporosis screening strategy conducted in the Province of Liege with the cooperation of Liege Province Sante Rev Med Liege 2008 63 : 588 594.
44. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009 122 : S3 13.
45. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006 38 : 922 928.
46. Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 2009 10 : 2303 2315.
47. Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007 18 : 1023 1031.
48. Cleemput I, Neyt M, Thiry N, et al. Valeurs seuils pour le rapport coût-efficacité en soins de santé. Health Technology Assessment (HTA). Bruxelles: Centre fédéral d'expertise des soins de santé (KCE) 2008. KCE Reports 100B (D/2008/10.273/95).
49. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation.
50. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009 in press. doi:10.1007/s00198-009-0976-0.
51. Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007 18 : 1311 1317.
52. Reginster JY, Rabenda V, Neuprez A Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006 38 (Suppl 1 S2 6.
53. Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007 120 : 251 256.
54. Sambrook P. Compliance with treatment in osteoporosis patients - an ongoing problem. Aust Fam Physician 2006 35 : 135 137.